Ascend is built on a simple philosophy: high quality science can be translated into leading edge products.
Ascend is a clinical-stage company developing innovative cancer treatments. We identify disease settings where targeting the disease microenvironment or specific cell types can improve clinical outcomes.
Our first product, ASN-002, is a treatment designed for direct delivery into tumors and our clinical program will focus on basal cell carcinoma, which is the most common form of skin cancer worldwide.
Our second product, ASN-004, is a pan-cancer active immunotherapy that is based on a clinically validated technology platform. Ascend has recently made improvements to the platform, which is reflected in ASN-004. Clinical studies for this product will focus on both early and late stage breast cancers.